Should Patients With COVID-19 Receive Post-Discharge Thromboprophylaxis? Short Answers to Frequently Asked Questions

1 Connors JM, Levy JH. Thromboinflammation and the hypercoagulability of COVID-19. J Thromb Haemost 2020; 18(7):1559–61. ConnorsJM LevyJH Thromboinflammation and the hypercoagulability of COVID-19 J Thromb Haemost 2020 18 7 1559 61 10.1111/jth.1484932302453 Search in Google Scholar

2 Becker RC. COVID-19 update: Covid-19-associated coagulopathy. J Thromb Thrombolysis 2020; 50:54–67. BeckerRC COVID-19 update: Covid-19-associated coagulopathy J Thromb Thrombolysis 2020 50 54 67 10.1007/s11239-020-02134-3722509532415579 Search in Google Scholar

3 Lüscher TF. Understanding COVID-19: in the end it is the endothelium-what else? Eur Heart J 2020; 41:3023–7. LüscherTF Understanding COVID-19: in the end it is the endothelium-what else? Eur Heart J 2020 41 3023 7 10.1093/eurheartj/ehaa706749964333216863 Search in Google Scholar

4 Giannis D, Ziogas IA, Gianni P. Coagulation disorders in coronavirus infected patients: COVID-19, SARS-CoV-1, MERS-CoV and lessons from the past. J Clin Virol 2020; 127:104362. doi: 10.1016/j.jcv.2020.104362. GiannisD ZiogasIA GianniP Coagulation disorders in coronavirus infected patients: COVID-19, SARS-CoV-1, MERS-CoV and lessons from the past J Clin Virol 2020 127 104362 10.1016/j.jcv.2020.104362 719527832305883 Open DOISearch in Google Scholar

5 Steffel J, Lüscher TF, Tanner FC. Tissue factor in cardiovascular diseases: molecular mechanisms and clinical implications. Circulation 2006; 113:722–31. SteffelJ LüscherTF TannerFC Tissue factor in cardiovascular diseases: molecular mechanisms and clinical implications Circulation 2006 113 722 31 10.1161/CIRCULATIONAHA.105.56729716461845 Search in Google Scholar

6 Bobescu E, Marceanu LG, Covaciu A, Vladau LA. Thrombosis, an important piece in the COVID-19 puzzle: from pathophysiology to therapy. Anatol J Cardiol 2021; 25(9):601–8. BobescuE MarceanuLG CovaciuA VladauLA Thrombosis, an important piece in the COVID-19 puzzle: from pathophysiology to therapy Anatol J Cardiol 2021 25 9 601 8 10.5152/AnatolJCardiol.2021.475844319534498590 Search in Google Scholar

7 Nopp S, Moik F, Jilma B, Pabinger I, Ay C. Risk of venous thromboembolism in patients with COVID-19: a systematic review and meta-analysis. Res Pract Thromb Haemost 2020; 4(7):1178–91. NoppS MoikF JilmaB PabingerI AyC Risk of venous thromboembolism in patients with COVID-19: a systematic review and meta-analysis Res Pract Thromb Haemost 2020 4 7 1178 91 10.1002/rth2.12439753713733043231 Search in Google Scholar

8 Dutch COVID & Thrombosis Coalition, Kaptein FHJ, Stals MAM, Grootenboers M, Braken SJE, Burggraaf JLI, et al. Incidence of thrombotic complications and overall survival in hospitalized patients with COVID-19 in the second and first wave. Thromb Res 2021; 199:143–8. Dutch COVID & Thrombosis Coalition KapteinFHJ StalsMAM GrootenboersM BrakenSJE BurggraafJLI Incidence of thrombotic complications and overall survival in hospitalized patients with COVID-19 in the second and first wave Thromb Res 2021 199 143 8 10.1016/j.thromres.2020.12.019783221833535120 Search in Google Scholar

9 Klok FA, Kruip MJHA, van der Meer NJM, Arbous MS, Gommers D, Kant KM, et al. Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: an updated analysis. Thromb Res 2020; 191:148–50. KlokFA KruipMJHA van der MeerNJM ArbousMS GommersD KantKM Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: an updated analysis Thromb Res 2020 191 148 50 10.1016/j.thromres.2020.04.041719210132381264 Search in Google Scholar

10 Desai R, Gandhi Z, Singh S, Sachdeva S, Manaktala P, Savani S, et al. Prevalence of pulmonary embolism in COVID-19: a pooled analysis. SN Compr Clin Med 2020; 2:2722–5. DesaiR GandhiZ SinghS SachdevaS ManaktalaP SavaniS Prevalence of pulmonary embolism in COVID-19: a pooled analysis SN Compr Clin Med 2020 2 2722 5 10.1007/s42399-020-00605-5759494333145478 Search in Google Scholar

11 Parra LM, Cantero M, Morrás I, Vallejo A, Diego I, Jiménez-Tejero E, et al. Hospital readmissions of discharged patients with COVID-19. Int J Gen Med 2020; 13:1359–66. ParraLM CanteroM MorrásI VallejoA DiegoI Jiménez-TejeroE Hospital readmissions of discharged patients with COVID-19 Int J Gen Med 2020 13 1359 66 10.2147/IJGM.S275775771943833299342 Search in Google Scholar

12 Bourguignon A, Beaulieu C, Belkaid W, Desilets A, Blais N. Incidence of thrombotic outcomes for patients hospitalized and discharged after COVID-19 infection, Thromb Res 2020; 196:491–3. BourguignonA BeaulieuC BelkaidW DesiletsA BlaisN Incidence of thrombotic outcomes for patients hospitalized and discharged after COVID-19 infection Thromb Res 2020 196 491 3 10.1016/j.thromres.2020.10.017755725633091702 Search in Google Scholar

13 Patell R, Bogue T, Koshy A, Bindal P, Merrill M, Aird WC, et al. Postdischarge thrombosis and hemorrhage in patients with COVID-19. Blood 2020; 136:1342–6. PatellR BogueT KoshyA BindalP MerrillM AirdWC Postdischarge thrombosis and hemorrhage in patients with COVID-19 Blood 2020 136 1342 6 10.1182/blood.2020007938748343332766883 Search in Google Scholar

14 Salisbury R, Iotchkova V, Jaafar S, Morton J, Sangha G, Shah A, et al. Incidence of symptomatic, image-confirmed venous thromboembolism following hospitalization for COVID-19 with 90-day follow-up. Blood Adv 2020; 4:6230–9. SalisburyR IotchkovaV JaafarS MortonJ SanghaG ShahA Incidence of symptomatic, image-confirmed venous thromboembolism following hospitalization for COVID-19 with 90-day follow-up Blood Adv 2020 4 6230 9 10.1182/bloodadvances.2020003349775700933351117 Search in Google Scholar

15 Roberts LN, Whyte MB, Georgiou L, Giron G, Czuprynska J, Rea C, et al. Postdischarge venous thromboembolism following hospital admission with COVID-19. Blood 2020; 136(11):1347–50. RobertsLN WhyteMB GeorgiouL GironG CzuprynskaJ ReaC Postdischarge venous thromboembolism following hospital admission with COVID-19 Blood 2020 136 11 1347 50 10.1182/blood.2020008086748343232746455 Search in Google Scholar

16 Rashidi F, Barco S, Kamangar F, Heresi GA, Emadi A, Kaymaz C, et al. Incidence of symptomatic venous thromboembolism following hospitalization for coronavirus disease 2019: prospective results from a multi-center study. Thromb Res 2021; 198:135–8. RashidiF BarcoS KamangarF HeresiGA EmadiA KaymazC Incidence of symptomatic venous thromboembolism following hospitalization for coronavirus disease 2019: prospective results from a multi-center study Thromb Res 2021 198 135 8 10.1016/j.thromres.2020.12.001783683733338976 Search in Google Scholar

17 Vlachou M, Drebes A, Candilio L, Weeraman D, Mir N, Murch N, et al. Pulmonary thrombosis in Covid-19: before, during and after hospital admission. J Thromb 2021; 51:978–84. VlachouM DrebesA CandilioL WeeramanD MirN MurchN Pulmonary thrombosis in Covid-19: before, during and after hospital admission J Thromb 2021 51 978 84 10.1007/s11239-020-02370-7777573833386559 Search in Google Scholar

18 Engelen MM, Vandenbriele C, Balthazar T, Claeys E, Gunst J, Guler I, et al. Venous thromboembolism in patients discharged after COVID-19 hospitalization. Semin Thromb Hemost 2021; 47(4):362–71. EngelenMM VandenbrieleC BalthazarT ClaeysE GunstJ GulerI Venous thromboembolism in patients discharged after COVID-19 hospitalization Semin Thromb Hemost 2021 47 4 362 71 10.1055/s-0041-172728433893631 Search in Google Scholar

19 Giannis D, Allen SL, Tsang J, Flint S, Pinhasov T, Williams S, et al. Postdischarge thromboembolic outcomes and mortality of hospitalized patients with COVID-19: the CORE-19 registry. Blood 2021; 20(137):2838–47. GiannisD AllenSL TsangJ FlintS PinhasovT WilliamsS Postdischarge thromboembolic outcomes and mortality of hospitalized patients with COVID-19: the CORE-19 registry Blood 2021 20 137 2838 47 10.1182/blood.2020010529803247433824972 Search in Google Scholar

20 Lund LC, Hallas J, Nielsen H, Koch A, Mogensen SH, Brun NC, Christiansen CF, et al. Post-acute effects of SARS-CoV-2 infection in individuals not requiring hospital admission: a Danish population-based cohort study. Lancet Infect Dis 2021; 21(10):1373–82. LundLC HallasJ NielsenH KochA MogensenSH BrunNC ChristiansenCF Post-acute effects of SARS-CoV-2 infection in individuals not requiring hospital admission: a Danish population-based cohort study Lancet Infect Dis 2021 21 10 1373 82 10.1016/S1473-3099(21)00211-5811020933984263 Search in Google Scholar

21 Venturelli S, Benatti SV, Casati M, Binda F, Zuglian G, Imeri G, et al. Surviving COVID-19 in Bergamo province: a post-acute outpatient re-evaluation, Epidemiol Infect 2021; 149:e32. https://doi.org/10.1017/S0950268821000145. VenturelliS BenattiSV CasatiM BindaF ZuglianG ImeriG Surviving COVID-19 in Bergamo province: a post-acute outpatient re-evaluation Epidemiol Infect 2021 149 e32 https://doi.org/10.1017/S0950268821000145. 10.1017/S0950268821000145787345433461632 Search in Google Scholar

22 Cuker A, Tseng EK, Nieuwlaat R, Angchaisuksiri P, Blair C, Dane K, et al. American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: July 2021 update on postdischarge thromboprophylaxis. Blood Adv 2022; 6(2):664–71. CukerA TsengEK NieuwlaatR AngchaisuksiriP BlairC DaneK American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: July 2021 update on postdischarge thromboprophylaxis Blood Adv 2022 6 2 664 71 10.1182/bloodadvances.2021005945856609734727173 Search in Google Scholar

23 Moores LK, Tritschler T, Brosnahan S, Carrier M, Collen JF, Doerschug K, et al. Prevention, diagnosis, and treatment of VTE in patients with coronavirus disease 2019: CHEST guideline and expert panel report. Chest 2020; 158(3):1143–63. MooresLK TritschlerT BrosnahanS CarrierM CollenJF DoerschugK Prevention, diagnosis, and treatment of VTE in patients with coronavirus disease 2019: CHEST guideline and expert panel report Chest 2020 158 3 1143 63 10.1016/j.chest.2020.05.559726585832502594 Search in Google Scholar

24 Zhai Z, Li C, Chen Y, Gerotziafas G, Zhang Z, Wan J, et al. Prevention and treatment of venous thromboembolism associated with coronavirus disease 2019 infection: a consensus statement before guidelines. Thromb Haemost 2020; 120(6):937–48. ZhaiZ LiC ChenY GerotziafasG ZhangZ WanJ Prevention and treatment of venous thromboembolism associated with coronavirus disease 2019 infection: a consensus statement before guidelines Thromb Haemost 2020 120 6 937 48 10.1055/s-0040-1710019729526732316065 Search in Google Scholar

25 Bikdeli B, Madhavan MV, Jimenez D, Chuich T, Dreyfus I, Driggin E, et al. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up: JACC state-of-the-art review. J Am Coll Cardiol 2020; 75(23):2950–73. BikdeliB MadhavanMV JimenezD ChuichT DreyfusI DrigginE COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up: JACC state-of-the-art review J Am Coll Cardiol 2020 75 23 2950 73 10.1016/j.jacc.2020.04.031716488132311448 Search in Google Scholar

26 Spyropoulos AC, Levy JH, Ageno W, Connors JM, Hunt BJ, Iba T, et al. Scientific and Standardization Committee Communication: clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID-19. J Thromb Haemost 2020; 18(8):1859–65. SpyropoulosAC LevyJH AgenoW ConnorsJM HuntBJ IbaT Scientific and Standardization Committee Communication: clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID-19 J Thromb Haemost 2020 18 8 1859 65 10.1111/jth.14929728384132459046 Search in Google Scholar

27 Scottish Intercollegiate Guidelines Network (SIGN) Guidelines. Prevention and management of venous thromboembolism in patients with COVID-19. Available at: www.sign.ac.uk. Accessed on 5 February 2022. Scottish Intercollegiate Guidelines Network (SIGN) Guidelines Prevention and management of venous thromboembolism in patients with COVID-19 Available at: www.sign.ac.uk. Accessed on 5 February 2022. Search in Google Scholar

28 Eswaran H, Jarmul JA, Shaheen AW, Meaux D, Long T, Saccoccio D, et al. Vascular thromboembolic events following COVID-19 hospital discharge: incidence and risk factors. Res Pract Thromb Haemost 2021; 5(2):292–5. EswaranH JarmulJA ShaheenAW MeauxD LongT SaccoccioD Vascular thromboembolic events following COVID-19 hospital discharge: incidence and risk factors Res Pract Thromb Haemost 2021 5 2 292 5 10.1002/rth2.12485793861333733027 Search in Google Scholar

29 Zuin M, Engelen MM, Barco S, Spyropoulos AC, Vanassche T, Hunt BJ, et al. Incidence of venous thromboembolic events in COVID-19 patients after hospital discharge: a systematic review and meta-analysis. Thromb Res 2022; 209:94–8. ZuinM EngelenMM BarcoS SpyropoulosAC VanasscheT HuntBJ Incidence of venous thromboembolic events in COVID-19 patients after hospital discharge: a systematic review and meta-analysis Thromb Res 2022 209 94 8 10.1016/j.thromres.2021.11.029864860434896917 Search in Google Scholar

30 Dobesh PP, Ahuja T, Davis GA, Fatodu H, Francis WH, Hull FP, et al. Venous thromboembolism in acute medically ill patients: identifying unmet needs and weighing the value of prophylaxis. Am J Manag Care 2018; 24(22 Suppl):S468–74. DobeshPP AhujaT DavisGA FatoduH FrancisWH HullFP Venous thromboembolism in acute medically ill patients: identifying unmet needs and weighing the value of prophylaxis Am J Manag Care 2018 24 22 Suppl S468 74 Search in Google Scholar

31 Effect of anticoagulation therapy on clinical outcomes in moderate to severe coronavirus Disease 2019 (COVID-19) – COVID-PREVENT. ClinicalTrials.gov Identifier: NCT04416048, Accessed on 3 February 2022. Effect of anticoagulation therapy on clinical outcomes in moderate to severe coronavirus Disease 2019 (COVID-19) – COVID-PREVENT ClinicalTrials.gov Identifier: NCT04416048, Accessed on 3 February 2022. Search in Google Scholar

32 Capell WH, Barnathan ES, Piazza G, Spyropoulos AC, Hsia J, Bull S, Lipardi C, Sugarmann C, Suh E, Rao JP, Hiatt WR, Bonaca MP. Rationale and design for the study of rivaroxaban to reduce thrombotic events, hospitalization, and death in outpatients with COVID-19: The PREVENT-HD Study. Am Heart J 2021; 235:12–23. CapellWH BarnathanES PiazzaG SpyropoulosAC HsiaJ BullS LipardiC SugarmannC SuhE RaoJP HiattWR BonacaMP Rationale and design for the study of rivaroxaban to reduce thrombotic events, hospitalization, and death in outpatients with COVID-19: The PREVENT-HD Study Am Heart J 2021 235 12 23 10.1016/j.ahj.2021.02.001787177533577800 Search in Google Scholar

33 Connors JM, Brooks MM, Sciurba FC, Krishnan JA, Bledsoe JR, Kindzelski A, Baucom AL, Kirwan BA, Eng H, Martin D, Zaharris E, Everett B, Castro L, Shapiro NL, Lin JY, Hou PC, Pepine CJ, Handberg E, Haight DO, Wilson JW, Majercik S, Fu Z, Zhong Y, Venugopal V, Beach S, Wisniewski S, Ridker PM; ACTIV-4B Investigators. Effect of antithrombotic therapy on clinical outcomes in outpatients with clinically Stable Symptomatic COVID-19: The ACTIV-4B Randomized Clinical Trial. JAMA 2021; 326(17):1703–12. ConnorsJM BrooksMM SciurbaFC KrishnanJA BledsoeJR KindzelskiA BaucomAL KirwanBA EngH MartinD ZaharrisE EverettB CastroL ShapiroNL LinJY HouPC PepineCJ HandbergE HaightDO WilsonJW MajercikS FuZ ZhongY VenugopalV BeachS WisniewskiS RidkerPM ACTIV-4B Investigators Effect of antithrombotic therapy on clinical outcomes in outpatients with clinically Stable Symptomatic COVID-19: The ACTIV-4B Randomized Clinical Trial JAMA 2021 326 17 1703 12 10.1001/jama.2021.17272850629634633405 Search in Google Scholar

34 Marchandot B, Trimaille A, Curtiaud A, Matsushita K, Jesel L, Morel O. Thromboprophylaxis: balancing evidence and experience during the COVID-19 pandemic. J Thromb Thrombolysis 2020; 50:799–808. MarchandotB TrimailleA CurtiaudA MatsushitaK JeselL MorelO Thromboprophylaxis: balancing evidence and experience during the COVID-19 pandemic J Thromb Thrombolysis 2020 50 799 808 10.1007/s11239-020-02231-3737274032696172 Search in Google Scholar

35 Mazzaccaro D, Giacomazzi F, Giannetta M, Varriale A, Scaramuzzo R, Modafferi A, et al. Non-overt coagulopathy in non-ICU patients with mild to moderate COVID-19 pneumonia. J Clin Med 2020; 9:1781. doi: 10.3390/jcm9061781. MazzaccaroD GiacomazziF GiannettaM VarrialeA ScaramuzzoR ModafferiA Non-overt coagulopathy in non-ICU patients with mild to moderate COVID-19 pneumonia J Clin Med 2020 9 1781 10.3390/jcm9061781 735565132521707 Open DOISearch in Google Scholar

36 Ambrosino P, Di Minno A, Maniscalco M, Di Minno MND. COVID-19 and venous thromboembolism: current insights and prophylactic strategies. Ann Med 2020; 52:239–42. doi: 10.1080/07853890.2020.1791355. AmbrosinoP Di MinnoA ManiscalcoM Di MinnoMND COVID-19 and venous thromboembolism: current insights and prophylactic strategies Ann Med 2020 52 239 42 10.1080/07853890.2020.1791355 787792032619360 Open DOISearch in Google Scholar

37 Panigada M, Bottino N, Tagliabue P, Grasselli G, Novembrino C, Chantarangkul V, et al. Hypercoagulability of COVID-19 patients in intensive care unit: a report of thromboelastography findings and other parameters of hemostasis. J Thromb Haemost 2020; 18:1738–42. PanigadaM BottinoN TagliabueP GrasselliG NovembrinoC ChantarangkulV Hypercoagulability of COVID-19 patients in intensive care unit: a report of thromboelastography findings and other parameters of hemostasis J Thromb Haemost 2020 18 1738 42 10.1111/jth.1485032302438 Search in Google Scholar

38 Thachil J, Juffermans NP, Ranucci M, Connors JM, Warkentin TE, Ortel TL, et al. ISTH DIC subcommittee communication on anticoagulation in COVID-19. J Thromb Haemost 2020; 18(9):2138–44. ThachilJ JuffermansNP RanucciM ConnorsJM WarkentinTE OrtelTL ISTH DIC subcommittee communication on anticoagulation in COVID-19 J Thromb Haemost 2020 18 9 2138 44 10.1111/jth.15004740484632881336 Search in Google Scholar

39 Spyropoulos AC, Lipardi C, Xu J, Peluso C, Spiro TE, De Sanctis Y, et al. Modified IMPROVE VTE Risk score and elevated D-dimer identify a high venous thromboembolism risk in acutely ill medical population for extended thromboprophylaxis. TH Open 2020; 4(1):e59–e65. SpyropoulosAC LipardiC XuJ PelusoC SpiroTE De SanctisY Modified IMPROVE VTE Risk score and elevated D-dimer identify a high venous thromboembolism risk in acutely ill medical population for extended thromboprophylaxis TH Open 2020 4 1 e59 e65 10.1055/s-0040-1705137706976232190813 Search in Google Scholar

40 Lopes RD, de Barros E, Silva PGM, Furtado RHM, Macedo AVS, Bronhara B, et al. Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial. Lancet 2021; 397(10291):2253–63. LopesRD de BarrosE SilvaPGM FurtadoRHM MacedoAVS BronharaB Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial Lancet 2021 397 10291 2253 63 10.1016/S0140-6736(21)01203-4817777034097856 Search in Google Scholar

41 Ramacciotti E, Barile Agati L, Calderaro D, Aguiar VCR, Spyropoulos AC, de Oliveira CCC, et al. Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial. Lancet 2022; 399(10319):50–9. RamacciottiE Barile AgatiL CalderaroD AguiarVCR SpyropoulosAC de OliveiraCCC Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial Lancet 2022 399 10319 50 9 10.1016/S0140-6736(21)02392-8867388134921756 Search in Google Scholar

42 Factor Xa Inhibitor versus standard of care heparin in hospitalized patients with COVID-19 (XACT). ClinicalTrials.gov Identifier: NCT04640181, Accessed on 22 February 2022. Factor Xa Inhibitor versus standard of care heparin in hospitalized patients with COVID-19 (XACT) ClinicalTrials.gov Identifier: NCT04640181, Accessed on 22 February 2022. Search in Google Scholar

43 Apixaban for prophylaxis of thromboembolic outcomes in COVID-19 – the Apollo trial. ClinicalTrials.gov Identifier: NCT04746339, Accessed on 22 February 2022. Apixaban for prophylaxis of thromboembolic outcomes in COVID-19 – the Apollo trial ClinicalTrials.gov Identifier: NCT04746339, Accessed on 22 February 2022. Search in Google Scholar

44 Helping Alleviate the longer-term consequences of COVID-19 (HEAL-COVID): a national platform trial. ClinicalTrials.gov Identifier: NCT04801940, Accessed on 22 February 2022. Helping Alleviate the longer-term consequences of COVID-19 (HEAL-COVID): a national platform trial ClinicalTrials.gov Identifier: NCT04801940, Accessed on 22 February 2022. Search in Google Scholar

45 ACTIV4c: COVID-19 post-hospital thrombosis prevention study – clinical trial. ClinicalTrials.gov Identifier: NCT04650087, Accessed on 22 February 2022. ACTIV4c: COVID-19 post-hospital thrombosis prevention study – clinical trial ClinicalTrials.gov Identifier: NCT04650087, Accessed on 22 February 2022. Search in Google Scholar

46 Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost 2020; 18:1094–9. TangN BaiH ChenX GongJ LiD SunZ Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy J Thromb Haemost 2020 18 1094 9 10.1111/jth.1481732220112 Search in Google Scholar

47 Ayerbe L, Risco C, Ayis S. The association between treatment with heparin and survival in patients with Covid-19. J Thromb Thrombolysis 2020; 50:298–301. AyerbeL RiscoC AyisS The association between treatment with heparin and survival in patients with Covid-19 J Thromb Thrombolysis 2020 50 298 301 10.1007/s11239-020-02162-z726134932476080 Search in Google Scholar

48 Hermans C, Lambert C. Impact of the COVID-19 pandemic on therapeutic choices in thrombosis-hemostasis. J Thromb Haemost 2020; 18:1794–5. HermansC LambertC Impact of the COVID-19 pandemic on therapeutic choices in thrombosis-hemostasis J Thromb Haemost 2020 18 1794 5 10.1111/jth.14845726240332294321 Search in Google Scholar

49 Marc F, Moldovan C, Hoza A, Restea P, Sachelarie L, Romila LE, et al. Evaluation of hepatic biochemical parameters during antiviral treatment in COVID-19 patients. Biology (Basel) 2021; 11(1):13. doi: 10.3390/biology11010013. PMID: 35053011; PMCID: PMC8772810. MarcF MoldovanC HozaA ResteaP SachelarieL RomilaLE Evaluation of hepatic biochemical parameters during antiviral treatment in COVID-19 patients Biology (Basel) 2021 11 1 13 10.3390/biology11010013 PMID: 35053011; PMCID: PMC8772810. 877281035053011 Open DOISearch in Google Scholar

50 Task Force for the Management of COVID-19 of the European Society of Cardiology. ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2-care pathways, treatment, and follow-up. Eur Heart J 2022; 43(11):1059–103. Task Force for the Management of COVID-19 of the European Society of Cardiology ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2-care pathways, treatment, and follow-up Eur Heart J 2022 43 11 1059 103 10.1093/eurheartj/ehab697869000634791154 Search in Google Scholar